|
IN SITE
|
 |
BMC Urol. 2005; 5: 1.
doi: 10.1186/1471-2490-5-1. Published online 2005 January 10.
Copyright © 2005
Ragavan et al; licensee BioMed Central Ltd.
Is DRE essential for the follow up of prostate
cancer patients? A prospective audit of 194 patients
Narasimhan Ragavan,1 Vijay
K Sangar,1 Sujoy Gupta,1 Jennifer Herdman,1 Shyam
S Matanhelia,1 Michael E Watson,1 and Rosemary
A Blades1
1Department of Urology,
Lancashire Teaching Hospitals NHS Trust, Preston, Lancashire,
United Kingdom
Received September 27, 2004; Accepted January 10, 2005.
|
Background
Prostate cancer
follow up forms a substantial part of the urology outpatient
workload. Nurse led prostate cancer follow up clinics are becoming
more common. Routine follow-up may involve performing DRE, which
may require training.
Objectives
The aim of this
audit was to assess the factors that influenced the change in
the management of prostate cancer patients during follow up.
This would allow us to pave the way towards a protocol driven
follow up clinic led by nurse specialists without formal training
in DRE.
Results
194 prostate
cancer patients were seen over a period of two months and all
the patients had DRE performed on at least one occasion. The
management was changed in 47 patients. The most common factor
influencing this change was PSA trend. A change in DRE findings
influenced advancement of the clinic visit in 2 patients.
Conclusions
PSA is the most
common factor influencing change in the management of these patients.
Nurse specialists can run prostate cancer follow-up clinics in
parallel to existing consultant clinics and reserve DRE only
for those patients who have a PSA change or have onset of new
symptoms. However larger studies are required involving all the
subgroups of patients to identify the subgroups of patients who
will require DRE routinely.
|
Prostate cancer
ranks first amongst all male urological cancers [1].
In the UK, 26027 new patients were diagnosed with prostate cancer
during 2001 [1].
The evidence suggests an increasing trend in the incidence in
the recent years, being 18201 in 1997 [2].
Nonetheless, better treatment modalities and earlier detection
has resulted in a decrease in cancer related mortality [3].
This is shown in the age-standardized death rate per million
population for prostate cancer, being 302 and 274 in 1991 and
2001 respectively.
Widespread PSA
testing and increased awareness has led to the detection of early
prostate cancer in many patients [4].
This has probably resulted in more patients requiring long periods
of follow up. Nurse Specialists in UK health care system have
evolved to share the increasing demand on the clinicians to meet
the targets and waiting times in all the specialties. In urology,
Nurse Specialists have assumed various roles including prostate
assessment clinics, urodynamics and flexible cystoscopy [5].
In some health care trusts, Nurse Specialists are involved in
the follow up of treated prostate cancer patients.
Faithfull et
al studied the use of telephone follow up of prostate cancer
patients by nurse specialists. They found that this method of
follow-up at 3, 6 and 12 weeks post radiotherapy was effective
and economical [6].
In addition a study on the follow-up of prostate cancer patients
by on-demand contact with a nurse specialist was found to be
as effective as traditional outpatient follow up by urologists
[7].
The EAU guidelines
[8]
suggest that prostate cancer patients should be followed at regular
intervals with a disease specific history and PSA estimation
supplemented by digital rectal examination. This would suggest
that all Nurse Specialists undertaking the role of follow-up
of such patients should be trained in DRE. Data on the role of
DRE in the follow up of prostate cancer patients is available
only for the subgroup of patients who have had treatment with
curative intent (radical prostatectomy or radical radiotherapy)
and these studies show that PSA trend plays a more important
role than DRE. However there is limited data available on the
role of DRE and other factors (e.g. LUTS, Bone pain etc) in the
follow up of diagnosed prostate cancer patients in the general
setting involving all treatment varieties which is likely to
be encountered in a nurse led follow up clinic.
The aim of this
audit was to prospectively assess the various factors that influence
a change in the management of the prostate cancer patients on
follow up and to highlight the feasibility of nurse led clinics
for the follow up of prostate cancer patients.
|
Over a two-month
period (Dec 2002Jan 2003) all the prostate cancer patients being
followed up in the Urology outpatient clinics at our institution
were audited prospectively. The patients were seen by a Consultant,
Specialist Registrar or Senior House Officer. The period of follow-up,
initial stage of the disease, management modality, consecutive
PSA values and consecutive DRE findings (if available) were recorded
on specifically designed data collection forms. All the patients
had DRE done on at least one occasion. The change in the management
was defined as any alteration in the follow-up pattern; either
as an advancement or postponement of a future appointment, the
need for further investigation or treatment, the admission of
a patient and the referral to a different specialist, for example
an Oncologist or Palliative Care specialist
The attending
physicians were requested to record whether there was any change
in the management and which factors influenced the change. They
were specifically requested to record whether DRE influenced
a change.
|
During the period
studied 194 patients being followed up for treated prostate cancer
were included. The mean age was 74.8 years and the stages at
initial diagnosis were: T1 (n = 73), T2 (n = 63), T3 (n = 44),
T4 (n = 14). Ten patients had metastatic disease. The management
modalities that these patients had undergone included: hormonal
manipulation (68), orchidectomy (8), radical radiotherapy with
hormonal manipulation (15), radical radiotherapy (48), radical
prostatectomy (21), brachytherapy (1) and active surveillance
(33) (Table 1).
The management changed in 47 of 194 (24%) patients. The factors
that influenced the changes included PSA trend (n = 27), LUTS
(n = 10), bone pain (n = 4), change in DRE findings (n = 2) and
other factors namely abnormal renal functions (n = 1), hematochezia
(n = 1), pruritis (n = 1) and erectile dysfunction (n = 1) (Table 2).
In this audit
PSA trend was the most common factor that resulted in a management
change. In the two patients there was a change in DRE findings
(progression from T2b disease to T3 disease
as observed by the assessor). This only resulted in the subsequent
visit being sooner than planned.
|
The follow up
of patients with prostate cancer has traditionally included a
disease specific history, serial PSA estimations and a DRE. The
roles of PSA and DRE have been extensively evaluated in the diagnosis
of prostate cancer patients [9,10].
There have only been a few studies questioning the importance
of DRE in the follow up of patients treated with a curative intent
[[11-13]
and [14]].
These have been based on groups of patients undergoing specific
treatments. These studies concluded that DRE is unnecessary in
the follow up of patients if PSA is undetectable. However there
have been rare case reports describing local or systemic recurrence
in the absence of detectable PSA [15,16].
There are no
reported studies in the English language assessing the role of
routine DRE in the follow up of all treated prostate cancer patients
in a general urology outpatient setting. In addition, studies
assessing the various factors (e.g LUTS, bone pains etc) that
influence a change in the management of these patients have not
been reported.
The present audit
shows that PSA trend is the most common factor influencing a
change in management whilst DRE plays a very limited role. Further,
there are other factors that influence a change in the management
of these patients' e.g. Bone pain and LUTS.
Although the
numbers of patients involved in this audit are moderate it would
suggest that Nurse Specialists could deliver the optimum care
in following up treated prostate cancer patients. Such Nurse
led clinics could be carried out in parallel to the existing
Consultant clinics thereby allowing the availability of medical
personnel to perform DRE where deemed necessary. A protocol to
perform DRE when there is an increase in PSA, onset of new symptoms
or worsening of existing symptoms would be suitable for such
a clinic. This audit suggests that Nurse Specialists need not
be trained to perform DRE before the establishment of such clinics.
However larger studies are required to identify subgroups of
treated prostate cancer patients who may require a DRE on a regular
basis. Alternatively nurses could be taught to undertake DRE
thereby further reducing clinician workload. This would require
a standardised and validated teaching method, which currently
does not exist. In our hospital this audit has influenced the
initiation of Nurse led prostate cancer follow up clinics conducted
in parallel to the consultant clinics.
|
The author(s)
declare that they have no competing interests.
|
NR Along with
VKS conceived the study, collected the data and jointly prepared
the text with VKS Along with NR conceived the study, assessed
the data and prepared the text, SG Participated in collecting
patients details and in the preparation of the text, JH helped
in approaching the patients and data collection, SSM Advised
regarding the design of the study and contributed to the text,
MEW Advised regarding the design of the study and contributed
to the text, RAB Overall supervision of the project with periodic
assessment on progress and preparation of text
All authors have
read and approved the final manuscript.
|
|
|
- Office of National Statistics Series MB1
no 32. Registration of cancer diagnosed in 2001, England.
London: Her Majesty's Stationary Office; 2001.
- Office of National Statistics Series MB1
no 28. Registrations of cancer diagnosed in 199597, England.
London: Her Majesty's Stationary Office; 1997.
- Offices for National Statistics Series DH2.No23.
Mortality Statistics by cause: England and Wales 1996. London:
Her Majesty's Stationary Office; 1996.
- Crawford ED. Epidemiology of prostate cancer. Urology 2003;62:312. [PubMed] [Full Text]
- Taylor JM, Pearce I, O'Flynn KJ. Nurse-led
cystoscopy: the next step. BJU Int 2002;90:456. [PubMed] [Full Text]
- Faithfull S, Corner J, Meyer L, Huddart
R, Dearnaley D. Evaluation of nurse-led follow up for patients
undergoing pelvic radiotherapy. Br J Cancer 2001;85:185364. 2001 Dec 14. [PubMed] [Full Text]
- Helgesen F, Andersson SO, Gustafsson O,
Varenhorst E, Goben B, Carnock S, Sehlstedt L, Carlsson P,
Holmberg L, Johansson JE. Follow-up of prostate cancer patients
by on-demand contacts with a Specialist nurse: a randomized
study. Scand J Urol Nephrol 2000;34:5561. [PubMed]
- European Association of Urology Guidelines.
Dukkerij Gelderland bv, Arnhem, The Netherlands; 2002.
- Yamamoto T, Ito K, Ohi M, Kubota Y, Suzuki
K, Fukabori Y, Kurokawa K, Yamanaka H. Diagnostic significance
of digital rectal examination and transrectal ultrasonography
in men with prostate-specific antigen levels of 4 NG/ML or
less. Urology 2001;58:9948. [PubMed] [Full Text]
- Potter SR, Horniger W, Tinzl M, Bartsch
G, Partin AW. Age, prostate-specific antigen, and digital
rectal examination as determinants of the probability of
having prostate cancer. Urology 2001;57:11004. [PubMed] [Full Text]
- Obek C, Neulander E, Sadek S, Soloway MS.
Is there a role for digital rectal examination in the follow
up of patients after radical prostatectomy. J
Urol 1999;162:7624. [PubMed] [Full Text]
- Pound CR, Christens-Barry OW, Gurganus
RT, Partin AW, Walsh PC. Digital rectal examination and imaging
studies are unnecessary in men with undetectable prostate
specific antigen following radical prostatectomy. J
Urol 1999;162:133740. [PubMed] [Full Text]
- Lattouf JB, Saad F. Digital Rectal Examination
Following Prostatectomy: Is it still necessary with the use
of PSA? Eur Urol 2003;43:3334. [PubMed] [Full Text]
- Johnstone PA, Mc Farland JT, Riffenburgh
RH, Amling CL. Efficacy of digital rectal examination after
radiotherapy for prostate cancer. J Urol 2001;166:16847. [PubMed] [Full Text]
- Takayama TK, Krieger JN, True LD, Lange
PH. Recurrent prostate cancer despite undetectable prostate
specific antigen. J Urol 1992;148:1541. [PubMed]
- Goldrath DE, Messing EM. Prostate specific
antigen: not detectable despite tumor progression after radical
prostatectomy. J Urol 1989;142:1082. [PubMed]
|
 |
Table
1
Management
categories of the follow up prostate cancer patients
|
 |
Table
2
Factors
that influenced a change in management
|
|
Message
Board
To learn
more about Prostatitis Research
Today is : November 20, 2008
You
are visitor number:
Disclaimer
|
 |
|